ゲフィチニブにより皮膚病変を来たした一例

概要

論文の詳細を見る
We report on the cutaneous adverse reactions of gefitinib (Iressa), an orally active, selective epidermal growth factor (EGF) receptor tyrosine kinase inhibitor that blocks signal transduction pathways, in a 19-year-old woman with recurrent malignant glioma. When treated daily with 250 mg gefitinib (p.o), the patient developed severe itching (Grade 2) and seborrheia (Grade 2) in the scalp, and acneiform eruption on the face (Grade 1) and upper limbs (Grade 1). The application of fluocinonide lotion to her scalp did not improve the symptoms, but the antihistaminic ebastine was effective. These cutaneous adverse reactions result from of gefitinib's direct interference with EGF receptor signaling in the skin and further studies should be conducted to elucidate the mechanisms by which they occur.
日本医療薬学会の論文
2004-05-10